Chronic Lymphocytic Leukemia Clinical Trials in New York, New York

17 studies are recruiting for chronic lymphocytic leukemia in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

   This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   632 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04269902 on ClinicalTrials.gov

2. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

   The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center Mskcc, New York, New York

   Locations

   130 in total

   Run by

   BeOne Medicines

   See if you can join NCT06846671 on ClinicalTrials.gov

3. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov

4. A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

   The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Locations

   214 in total

   Run by

   BeOne Medicines

   See if you can join NCT06973187 on ClinicalTrials.gov

5. A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

   The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocyti…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Locations

   114 in total

   Run by

   BeOne Medicines

   See if you can join NCT07277231 on ClinicalTrials.gov

6. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, New York

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

7. A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

   This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study interve…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York

   Locations

   50 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07218341 on ClinicalTrials.gov

8. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

9. A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

   The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituxi…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center Mskcc, New York, New York

   Locations

   195 in total

   Run by

   BeOne Medicines

   See if you can join NCT06943872 on ClinicalTrials.gov

10. Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

    The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    2 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT06849713 on ClinicalTrials.gov

11. A Long-term Extension Study of PCI-32765 (Ibrutinib)

    The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Weill Medical College of Cornell University, New York, New York

    Locations

    175 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT01804686 on ClinicalTrials.gov

12. A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

    Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetocl…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Icahn School of Medicine at Mount Sinai /ID# 266328, New York, New York

    Locations

    70 in total

    Run by

    AbbVie

    See if you can join NCT06428019 on ClinicalTrials.gov

13. Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

    This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venetoclax is in a class of medications called B-cell lymphoma-2 …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

    Locations

    7 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT07218510 on ClinicalTrials.gov

14. A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

    The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studie…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York

    Locations

    38 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06876649 on ClinicalTrials.gov

15. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

    Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York

    Locations

    36 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06876662 on ClinicalTrials.gov

16. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Weill Cornell, New York, New York

    Locations

    36 in total

    Run by

    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov

17. Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

    This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mount Sinai- Icahn School of Medicine, New York, New York

    Locations

    4 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT04679012 on ClinicalTrials.gov